Ocular Therapeutix (OCUL) Stock Price, News & Analysis

Company Overview

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based formulation and delivery technologies to create sustained-release treatments intended to improve drug delivery, reduce dosing frequency and address unmet needs in ophthalmology.

Its commercial product is DEXTENZA, a corticosteroid ophthalmic insert that is placed in the canaliculus by a healthcare professional. DEXTENZA is approved in the United States for the treatment of ocular itching associated with allergic conjunctivitis and for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix is also advancing a pipeline of investigational treatments for retinal diseases and other ophthalmic conditions, including therapies designed for longer-duration drug delivery.

Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix primarily serves the U.S. ophthalmology market. The company is led by co-founder Antony P. Marucci, who serves as president and chief executive officer. Its products and development programs are supported by research, clinical development and commercial activities focused on the United States.

Key Stats

• Today's Range: $6.80 to $6.98
• 50-Day Range: $6.96 to $11.73
• 52-Week Range: $6.23 to $16.44
• Volume: 234,188 shs
• Average Volume: 3.98 million shs
• Market Capitalization: $1.51 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.33
• Consensus Rating: Moderate Buy

Ocular Therapeutix Stock Analysis - MarketRank™

Ocular Therapeutix scored higher than 55% of companies evaluated by MarketBeat, and ranked 434th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ocular Therapeutix has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Ocular Therapeutix has a consensus price target of $24.33, representing about 249.6% upside from its current price of $6.96.

Amount of Analyst Coverage

Ocular Therapeutix has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ocular Therapeutix are expected to grow in the coming year, from ($1.47) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ocular Therapeutix is -4.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ocular Therapeutix is -4.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ocular Therapeutix has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.07% of the float of Ocular Therapeutix has been sold short.

Short Interest Ratio / Days to Cover

Ocular Therapeutix has a short interest ratio ("days to cover") of 14.19, which indicates bearish sentiment.

Change versus previous month

Short interest in Ocular Therapeutix has recently increased by 6.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ocular Therapeutix does not currently pay a dividend.

Dividend Growth

Ocular Therapeutix does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.16

News Sentiment

Ocular Therapeutix has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Ocular Therapeutix this week, compared to 6 articles on an average week.

Search Interest

Only 13 people have searched for OCUL on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

MarketBeat Follows

4 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ocular Therapeutix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $321,827.00 in company stock.

Percentage Held by Insiders

3.10% of the stock of Ocular Therapeutix is held by insiders.

Percentage Held by Institutions

59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 10/05/2026
• Chardan's 10th Annual Healthcare Conference: 10/20/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:OCUL
• CIK: 1393434
• Web: www.ocutx.com
• Phone: (781) 357-4000
• Fax: 781-357-4001
• Employees: 325
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Ocular Therapeutix: $24.33
• High Price Target: $30.00
• Low Price Target: $18.00
• Potential Upside/Downside: +249.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$265.94 million
• Net Margins: -579.10%
• Pretax Margin: -579.10%
• Return on Equity: -59.89%
• Return on Assets: -45.99%

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 13.10
• Quick Ratio: 13.03

Sales & Book Value

• Annual Sales: $51.95 million
• Price / Sales: 29.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.07 per share
• Price / Book: 2.27

Miscellaneous

• Outstanding Shares: 219,620,000
• Free Float: 212,808,000
• Market Cap: $1.53 billion
• Optionable: Optionable
• Beta: 1.00